Literature DB >> 33445800

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer's Disease.

Anna Bonaterra-Pastra1, Sofia Fernández-de-Retana1, Andrea Rivas-Urbina2, Núria Puig2, Sònia Benítez2, Olalla Pancorbo3, David Rodríguez-Luna3, Francesc Pujadas4, Maria Del Mar Freijo5, Silvia Tur6, Maite Martínez-Zabaleta7, Pere Cardona Portela8, Rocío Vera9, Lucia Lebrato-Hernández10, Juan F Arenillas11,12, Soledad Pérez-Sánchez13, Joan Montaner1,10,13,14, Jose Luis Sánchez-Quesada2,15, Mar Hernández-Guillamon1.   

Abstract

Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer's disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation.

Entities:  

Keywords:  Alzheimer’s disease; apolipoproteins; cerebral amyloid angiopathy; lipid profile; lipoprotein composition

Year:  2021        PMID: 33445800      PMCID: PMC7828227          DOI: 10.3390/biomedicines9010072

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  78 in total

1.  The APOC3 SstI polymorphism is weakly associated with sporadic Alzheimer's disease in a Chinese population.

Authors:  Yan Sun; Jiajun Shi; Sizhong Zhang; Mouni Tang; Haiying Han; Yangbo Guo; Cui Ma; Xiehe Liu; Tao Li
Journal:  Neurosci Lett       Date:  2005-02-16       Impact factor: 3.046

Review 2.  Association between statin use and intracerebral hemorrhage: a systematic review and meta-analysis.

Authors:  C Lei; B Wu; M Liu; Y Chen
Journal:  Eur J Neurol       Date:  2013-10-07       Impact factor: 6.089

3.  Functional and structural properties of lipid-associated apolipoprotein J (clusterin).

Authors:  M Calero; T Tokuda; A Rostagno; A Kumar; B Zlokovic; B Frangione; J Ghiso
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

4.  Characterization of apolipoprotein J-Alzheimer's A beta interaction.

Authors:  E Matsubara; B Frangione; J Ghiso
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

5.  Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells.

Authors:  Hyun Beom Song; Hyoung-Oh Jun; Jin Hyoung Kim; Young Suk Yu; Kyu-Won Kim; Bon Hong Min; Jeong Hun Kim
Journal:  Oncol Rep       Date:  2013-10-01       Impact factor: 3.906

6.  Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ.

Authors:  J Scott Miners; Polly Clarke; Seth Love
Journal:  Brain Pathol       Date:  2016-07-08       Impact factor: 6.508

7.  Standardization of a method to evaluate the antioxidant capacity of high-density lipoproteins.

Authors:  Elena de Juan-Franco; Antonio Pérez; Vicent Ribas; Juan Antonio Sánchez-Hernández; Francisco Blanco-Vaca; Jordi Ordóñez-Llanos; José Luis Sánchez-Quesada
Journal:  Int J Biomed Sci       Date:  2009-12

8.  Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes.

Authors:  Jose Luis Sánchez-Quesada; Irene Vinagre; Elena De Juan-Franco; Juan Sánchez-Hernández; Rosa Bonet-Marques; Francisco Blanco-Vaca; Jordi Ordóñez-Llanos; Antonio Pérez
Journal:  Cardiovasc Diabetol       Date:  2013-08-05       Impact factor: 9.951

Review 9.  Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage.

Authors:  Yingxu Ma; Zhaokai Li; Liang Chen; Xiangping Li
Journal:  Lipids Health Dis       Date:  2016-03-01       Impact factor: 3.876

10.  Systems proteomic analysis reveals that clusterin and tissue inhibitor of metalloproteinases 3 increase in leptomeningeal arteries affected by cerebral amyloid angiopathy.

Authors:  A Manousopoulou; M Gatherer; C Smith; J A R Nicoll; C H Woelk; M Johnson; R Kalaria; J Attems; S D Garbis; R O Carare
Journal:  Neuropathol Appl Neurobiol       Date:  2016-10-05       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.